Insider Buying: Eyegate Pharmaceuticals, Inc. (EYEG) Insider Acquires $12,875.00 in Stock
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) insider Stephen From bought 12,500 shares of Eyegate Pharmaceuticals stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average cost of $1.03 per share, with a total value of $12,875.00. Following the acquisition, the insider now directly owns 272,465 shares in the company, valued at approximately $280,638.95. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) traded up 4.02% during mid-day trading on Friday, reaching $1.03. 101,264 shares of the company’s stock were exchanged. Eyegate Pharmaceuticals, Inc. has a 52-week low of $0.90 and a 52-week high of $3.90. The company has a 50-day moving average of $1.30 and a 200-day moving average of $1.85. The stock’s market cap is $17.72 million.
Several analysts recently commented on the stock. Noble Financial reaffirmed a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Friday, May 19th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Eyegate Pharmaceuticals in a report on Wednesday, June 14th.
A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Vanguard Group Inc. raised its position in Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,319 shares of the specialty pharmaceutical company’s stock after buying an additional 1,988 shares during the period. Vanguard Group Inc. owned 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent SEC filing. 1.85% of the stock is currently owned by institutional investors.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Stock Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.